Phase 1 trial of enzalutamide in combination with gemcitabine and nab-paclitaxel for the treatment of advanced pancreatic cancer
Conclusions Enzalutamide 160 mg daily in combination with gemcitabine and nab-paclitaxel can be safely administered with no unexpected toxicities. We also noticed preliminary signals of efficacy with this combination.
Source: Investigational New Drugs - Category: Drugs & Pharmacology Source Type: research
More News: Anemia | Cancer | Cancer & Oncology | Drugs & Pharmacology | Hypertension | Investigational New Drugs | Pancreas | Pancreatic Cancer | Thrombocytopenia | Toxicology